Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-bl (Q38558536)
Jump to navigation
Jump to search
scientific article published on 29 December 2016
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-bl |
scientific article published on 29 December 2016 |
Statements
1 reference
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-bl (English)
1 reference
Kristian Reich
1 reference
April W Armstrong
1 reference
Peter Foley
1 reference
Michael Song
1 reference
Yasmine Wasfi
1 reference
Bruce Randazzo
1 reference
Shu Li
1 reference
Y-K Shen
1 reference
Kenneth B Gordon
1 reference
29 December 2016
1 reference
1 reference
76
1 reference
3
1 reference
418-431
1 reference
Identifiers
1 reference
1 reference